Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)-Reference-Cited by-同舟云学术

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

Published:2016-03-04 Issue:5 Volume:63 Page:1430-1441
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Leroy Vincent¹,Angus Peter²,Bronowicki Jean‐Pierre³,Dore Gregory J.⁴,Hezode Christophe⁵,Pianko Stephen⁶,Pol Stanislas⁷,Stuart Katherine⁸,Tse Edmund⁹,McPhee Fiona¹⁰,Bhore Rafia¹¹,Jimenez‐Exposito Maria Jesus¹¹,Thompson Alexander J.¹²

Affiliation:

1. Clinique Universitaire d'Hepato‐Gastroentérologie, Pôle DigiduneCHU de Grenoble and Unité INSERM/Université Grenoble Alpes U823, IAPC Institut Albert BonniotGrenoble France

2. Austin HospitalHeidelberg Australia

3. INSERM U954, CHU de NancyUniversité de LorraineNancy France

4. St. Vincent's Hospital and Kirby InstituteUNSW AustraliaSydney Australia

5. CHU Henri MondorCréteil France

6. Monash Medical CentreClayton Australia

7. Hôpital CochinParis France

8. Gallipoli Medical Research FoundationGreenslopes Australia

9. South Australia HealthAdelaide Australia

10. Bristol‐Myers Squibb Research & DevelopmentWallingford CT

11. Bristol‐Myers Squibb Research & DevelopmentPrinceton NJ

12. St Vincent's Hospital and the University of MelbourneMelbourne Australia

Funder